• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Safety of oseltamivir during pregnancy: a comparative study using the EFEMERIS database

tetano

Editor, Senior Moderator
BJOG. 2014 Feb 11. doi: 10.1111/1471-0528.12617. [Epub ahead of print]
Safety of oseltamivir during pregnancy: a comparative study using the EFEMERIS database.
Beau AB, Hurault-Delarue C, Vial T, Montastruc JL, Damase-Michel C, Lacroix I.
Author information
Abstract
OBJECTIVE:

To compare pregnancy outcome between women exposed and unexposed to oseltamivir during pregnancy.
DESIGN:

A comparative observational cohort study of women exposed to oseltamivir during pregnancy.
SETTING:

A French prescription database (EFEMERIS) that includes data for pregnant women was used. EFEMERIS records prescribed and dispensed reimbursed drugs during pregnancy and pregnancy outcomes in Haute-Garonne, South West France.
POPULATION:

Women who delivered from 1 July 2004 to 31 December 2010.
METHODS:

The study compared exposed and unexposed pregnant women. Two women unexposed to oseltamivir were individually matched, by maternal age, month, and year of delivery, with one women exposed to oseltamivir. Multivariable conditional logistic regression and multivariable Cox proportional hazards regression were used to evaluate associations between each outcome and exposure to oseltamivir during pregnancy.
MAIN OUTCOME MEASURES:

Pregnancy loss for any cause, preterm delivery, low birthweight, neonatal pathology, and congenital malformation.
RESULTS:

A cohort of 337 (0.58% of women included in EFEMERIS) women exposed to oseltamivir were compared with 674 unexposed women. The risk for pregnancy loss (HR 1.52; 95 % CI 0.80-2.91), for preterm birth (adjusted OR 0.64; 95% CI 0.31-1.27), and for neonatal pathology (adjusted OR 0.62; 95% CI 0.23-1.54) did not differ between exposed and unexposed groups. When exposure during organogenesis was considered, one case of congenital anomaly (2.0%) among 49 exposed women and one case (1.0%) among 99 unexposed women were observed (crude OR 2.00; 95% CI 0.13-32.00).
CONCLUSIONS:

There was no significant association between adverse pregnancy outcomes and exposure to oseltamivir during pregnancy.

? 2014 Royal College of Obstetricians and Gynaecologists.
KEYWORDS:

EFEMERIS , Adverse pregnancy outcomes, influenza A (H1N1), oseltamivir, pregnancy

PMID:
24512604
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24512604
 
Back
Top Bottom